Home » Stocks » HRTX

Heron Therapeutics, Inc. (HRTX)

Stock Price: $17.64 USD 0.00 (0.00%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $17.82 +0.18 (1.02%) Jan 15, 6:24 PM
Market Cap 1.60B
Revenue (ttm) 103.12M
Net Income (ttm) -222.92M
Shares Out 90.85M
EPS (ttm) -2.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $17.64
Previous Close $17.64
Change ($) 0.00
Change (%) 0.00%
Day's Open 18.13
Day's Range 17.55 - 18.30
Day's Volume 980,993
52-Week Range 10.23 - 24.53

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 week ago

SAN DIEGO, Jan. 11, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-clas...

Zacks Investment Research - 2 weeks ago

Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

PRNewsWire - 2 months ago

SAN DIEGO, Nov. 11, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-clas...

The Motley Fool - 2 months ago

This biotech titan should be a top player on the merger and acquisition scene next year.

Other stocks mentioned: BIIB, AUPH, SAVA
Zacks Investment Research - 2 months ago

Heron Therapeutics (HRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

InvestorPlace - 2 months ago

It's a good time to separate the weak from the strong. The post 7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio appeared first on InvestorPlace.

Other stocks mentioned: CBPO, GLPG, ILMN, IONS, RGNX, LGND
Zacks Investment Research - 3 months ago

Heron's (HRTX) Zynrelef gains a marketing nod from the European Commission for managing postoperative pain in surgical wounds among adult patients. Stock rises.

PRNewsWire - 3 months ago

SAN DIEGO, Sept. 28, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-cla...

PRNewsWire - 4 months ago

SAN DIEGO, Sept. 11, 2020 /PRNewswire/ -- Heron Therapeutics, Inc.

PRNewsWire - 4 months ago

SAN DIEGO, Sept. 8, 2020 /PRNewswire/ -- Heron Therapeutics, Inc.

The Motley Fool - 5 months ago

Bargain hunters pounced on this beaten-down biotech stock last month. Here's why.

Zacks Investment Research - 5 months ago

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -3.39% and 38.64%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire - 5 months ago

SAN DIEGO, Aug. 5, 2020 /PRNewswire/ -- Heron Therapeutics, Inc.

Zacks Investment Research - 5 months ago

Heron Therapeutics (HRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 6 months ago

Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.

Zacks Investment Research - 6 months ago

Heron's (HRTX) NDA seeking approval for pipeline candidate, HTX-011, for the management of postoperative pain gets CRL from the FDA, based on non-clinical issues. Shares down.

The Motley Fool - 6 months ago

Its non-opioid painkiller gets a rejection over non-clinical issues.

Zacks Investment Research - 6 months ago

Investors need to pay close attention to Heron Therapeutics (HRTX) stock based on the movements in the options market lately.

PRNewsWire - 6 months ago

SAN DIEGO, June 29, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-clas...

The Motley Fool - 7 months ago

Heron Therapeutics and Novavax are two key healthcare stocks to watch this month.

Other stocks mentioned: NVAX
Benzinga - 7 months ago

Heron Therapeutics (NASDAQ: HRTX) shares are trading higher on Wednesday after Guggenheim initiated coverage on the company's stock with a Buy rating and $24 price target.

The Motley Fool - 8 months ago

AbbVie, Adverum Biotechnologies, and Heron Therapeutics could all be gearing up for a strong May. Here's why.

Other stocks mentioned: ABBV, ADVM
Zacks Investment Research - 8 months ago

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 9.52% and 25.36%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

The Motley Fool - 9 months ago

Heron Therapeutics and Intercept Pharmaceuticals are too cheap to ignore right now.

Other stocks mentioned: ICPT
Zacks Investment Research - 10 months ago

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -12.07% and 0.81%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the...

Seeking Alpha - 10 months ago

Heron Therapeutics: Looking For Entry Following HTX-011 PDUFA Extension

Zacks Investment Research - 10 months ago

Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 11 months ago

Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Zacks Investment Research - 1 year ago

Heron Therapeutics is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Benzinga - 1 year ago

Biotech investment is risk fraught. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts.

Other stocks mentioned: AKCA, AMAG, AXSM, CRON, EIDX, LGND, PRTK, PTE, VKTX, XON, ZIOP
Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Heron Therapeutics, Inc. (HRTX).

Seeking Alpha - 1 year ago

Heron Therapeutics: Looking Solid Heading Into 2020

Zacks Investment Research - 1 year ago

Heron Therapeutics (HRTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research - 1 year ago

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 30.00% and 25.64%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for th...

Zacks Investment Research - 1 year ago

Heron Therapeutics (HRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 1 year ago

These two biotech stocks are poised for big gains next year.

Other stocks mentioned: AMRN
InvestorPlace - 1 year ago

These are five stocks to consider buying because of significant insider buying activity. Insiders only buy for one reason: to make money.

Other stocks mentioned: FDX, IMMU, KALV, VBIV
The Motley Fool - 1 year ago

A high-risk transformative move sent one of these stocks lower.

Other stocks mentioned: AVT, HPQ
Seeking Alpha - 1 year ago

The steep sell-off in biotech over the past two weeks has obscured some positive developments around Heron Therapeutics.

Zacks Investment Research - 1 year ago

Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

The Motley Fool - 1 year ago

You should never blindly follow the crowd, but it pays to watch what the biggest and brightest on Wall Street are doing.

Other stocks mentioned: AMZN, WPM
Seeking Alpha - 1 year ago

Despite better than expected Q2 results, the stock of small biopharma Heron Therapeutics sits near 52-week lows.

GuruFocus - 1 year ago

The biotechnology industry is an exciting one. A mix of technology and a better understanding of the human body has led to several very exciting breakthroughs over the past several years, and ...

Other stocks mentioned: AMRN
The Motley Fool - 1 year ago

These three biotech stocks might be outstanding buys right now.

Other stocks mentioned: CELG, IOVA
The Motley Fool - 1 year ago

Amarin and Heron Therapeutics could turn out to be outstanding bargains.

Other stocks mentioned: AMRN
Seeking Alpha - 1 year ago

Not all CRLs are created equal. Investors likely overreacted to the recent announcement of Heron’s Complete Response Letter.

The Motley Fool - 1 year ago

These stocks are bargains.

Other stocks mentioned: CVS, ILMN
Seeking Alpha - 1 year ago

The FDA gave Heron Therapeutics' HTX-011 drug a CRL after issues were noted with the CMC and non-clinical information portion of the application.

The Motley Fool - 1 year ago

Heron's falling share price last month turned out to be a bad omen.

Seeking Alpha - 1 year ago

Heron is a fundamentally sound company undergoing what is seemingly a temporary share price depreciation.

About HRTX

Heron Therapeutics, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclop... [Read more...]

Industry
Biotechnology
IPO Date
Aug 26, 1987
CEO
Barry Quart
Employees
231
Stock Exchange
NASDAQ
Ticker Symbol
HRTX
Full Company Profile

Financial Performance

In 2019, HRTX's revenue was $145.97 million, an increase of 88.41% compared to the previous year's $77.47 million. Losses were -$204.75 million, 14.5% more than in 2018.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for HRTX stock is "Strong Buy." The 12-month stock price forecast is 32.10, which is an increase of 81.97% from the latest price.

Price Target
$32.10
(81.97% upside)
Analyst Consensus: Strong Buy